GHRH receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
ISBN 0-451-23706-4 OCLC 741538553 Megellas, James. All the Way to Berlin: A Paratrooper at War in Europe. New York: Ballantine Books, 2003. ISBN 0-89141-784-2 OCLC 50810144 Mrozek, Steven J. 82nd Airborne Division. Paducah, Ky: Turner Pub. Co, 1997. ISBN 1-56311-364-3 OCLC 52963023 Nordyke, Phil. All American, All the Way: The Combat History of the 82nd Airborne Division in World War II. St. Paul, MN: Zenith Press, 2005. ISBN 0-7603-2201-5 OCLC 60757547 Nordyke, Phil. The All Americans in World War II: A Photographic History of the 82nd Airborne Division at War. St. Paul, MN: Zenith Press, 2006. ISBN 0-7603-2617-7 OCLC 64961665 Pushies, Fred (2008). 82nd Airborne. Military Power. Minneapolis, Minnesota: Zenith Press. p. 128. ISBN 978-0-7603-3465-2. OCLC 199464749. Ruggero, Ed. Combat Jump: The Young Men Who Led the Assault into Fortress Europe, July 1943. New York: HarperCollins, 2003. ISBN 0-06-008875-3 OCLC 51978036 Saunders, Tim. Nijmegen, Grave, and Groesbeek. Barnsley, South Yorkshire: Leo Cooper, 2001. ISBN 0-85052-815-1 OCLC 49594764 Thompson, Leroy. The All Americans: The 82nd Airborne. Newton Abbot, Devon: David & Charles Publishers, 1988. ISBN 0-7153-9182-8 OCLC 19393819 Zinsmeister, Karl. Boots on the Ground: A Month with the 82nd Airborne in the Battle for Iraq. New York: Truman Talley Books/St. Martin's Press, 2003. ISBN 0-312-32663-7 OCLC 52775207 Zinsmeister, Karl, Dan Jurgens, and Raul Trevino. Combat Zone: True Tales of GIs in Iraq. New York, NY: Marvel Comics, 2005. ISBN 0-7851-1516-1 OCLC 61373604
The Government of India refused the offer from Union Carbide, and claimed US$3.3 billion. The Indian Supreme Court told both sides to come to an agreement and "start with a clean slate" in November 1988. Eventually, in an out-of-court settlement reached in February 1989, Union Carbide agreed to pay US$470 million for damages caused in the Bhopal disaster. The amount was immediately paid. Throughout 1990, the Indian Supreme Court heard appeals against the settlement. In October 1991, the Court upheld the original $470 million, dismissing any other outstanding petitions that challenged the original decision. It ordered the Indian government "to purchase, out of settlement fund, a group medical insurance policy to cover 100,000 persons who may later develop symptoms" and cover any shortfall in the settlement fund. It also requested UCC and its subsidiary UCIL "voluntarily" fund a hospital in Bhopal, at an estimated $17 million, to specifically treat victims of the Bhopal disaster. The company agreed to this.
Tetrahydrocannabinol (THC) is a cannabinoid found in cannabis. It is the principal psychoactive constituent of Cannabis and one of at least 113 total cannabinoids identified on the plant. Although the chemical formula for THC (C21H30O2) describes multiple isomers, the term THC usually refers to the delta-9-THC isomer with chemical name (−)-trans-Δ9-tetrahydrocannabinol. THC, also known pharmaceutically as dronabinol, is used medically to relieve chemotherapy-induced nausea and HIV/AIDS-related anorexia. Nabiximols, a botanical drug which contains THC, is used medically to treat symptoms of multiple sclerosis, including spasticity and neuropathic pain. THC acts as a partial agonist at CB1 and CB2 cannabinoid receptors. THC can be administered orally, inhaled, or transdermally, with bioavailability and onset varying by route, and is extensively metabolized in the liver to active and inactive metabolites before being excreted in feces and urine. Side effects include red eyes, dry mouth, drowsiness, memory impairment, anxiety, and, with chronic use, cannabinoid hyperemesis syndrome. While human overdose is rare, THC can interact with other drugs and has a complex pharmacokinetic profile.
Sources: en.wikipedia.org
In 2009, 86% of cadmium was used in batteries, predominantly in rechargeable nickel–cadmium batteries. Nickel–cadmium cells have a nominal cell potential of 1.2 V. The cell consists of a positive nickel hydroxide electrode and a negative cadmium electrode plate separated by an alkaline electrolyte (potassium hydroxide). The European Union put a limit on cadmium in electronics in 2004 of 0.01%, with some exceptions, and in 2006 reduced the limit on cadmium content to 0.002%. Another type of battery based on cadmium is the silver–cadmium battery.
In addition to formalin, other chemical fixatives have been used. But, with the advent of immunohistochemistry (IHC) staining and diagnostic molecular pathology testing on these specimen samples, formalin has become the standard chemical fixative in human diagnostic histopathology. Fixation times for very small specimens are shorter, and standards exist in human diagnostic histopathology.
== Reception == Season 1 of Beast Games was released on Amazon Prime Video between December 2024 and February 2025 as ten episodes, released weekly. It became Prime Video's most watched unscripted series ever and its second largest series debut of 2025, though it was received poorly by critics. Several contestants alleged they were mistreated during production, resulting in a lawsuit against Donaldson's company and several others. On review aggregation website Rotten Tomatoes, the series has an approval rating of 20% based on 10 critic reviews, with an average rating of 5/10. Metacritic, which uses a weighted average, gave it a score of 38 out of 100 based on five critics, indicating "generally unfavorable" reviews. Several reviewers critiqued Donaldson's performance as loud and shallow and the show's lack of focus on its contestants. Naomi Fry of The New Yorker wrote that the use of contestants' numbers instead of their names made it difficult to empathize with them, unlike other reality shows. IGN, The Guardian, Vox, and PC Gamer criticized the show for closely following the premise of Squid Game while stripping away its dystopian tone. The financial aspects of the show have also come under scrutiny. Katie Notopoulos of Business Insider enjoyed the show, but she worried that it could communicate to children the lack of value in money.
A diet that is heavy on grains, fish, and vegetables and light on meat, eggs, and dairy products. Low-stress lifestyles, which are proven significantly less stressful than that of the mainland inhabitants of Japan. A caring community, where older adults are not isolated and are taken better care of. High levels of activity, where locals work until an older age than the average age in other countries, and more emphasis on activities like walking and gardening to keep active. Spirituality, where a sense of purpose comes from involvement in spiritual matters and prayer eases the mind of stress and problems. Although these factors vary from those mentioned in the previous study, the culture of Okinawa has proven these factors to be important in its large population of centenarians.
Sources: en.wikipedia.org
== History and classification == The first protein to be recognized as catalyzing the phosphorylation of another protein using ATP was observed in 1954 by Eugene P. Kennedy at which time he described a liver enzyme that catalyzed the phosphorylation of casein. In 1956, Edmond H. Fischer and Edwin G. Krebs discovered that the interconversion between phosphorylase a and phosphorylase b was mediated by phosphorylation and dephosphorylation. The kinase that transferred a phosphoryl group to Phosphorylase b, converting it to Phosphorylase a, was named Phosphorylase Kinase. Years later, the first example of a kinase cascade was identified, whereby Protein Kinase A (PKA) phosphorylates Phosphorylase Kinase. At the same time, it was found that PKA inhibits glycogen synthase, which was the first example of a phosphorylation event that resulted in inhibition. In 1969, Lester Reed discovered that pyruvate dehydrogenase was inactivated by phosphorylation, and this discovery was the first clue that phosphorylation might serve as a means of regulation in other metabolic pathways besides glycogen metabolism. In the same year, Tom Langan discovered that PKA phosphorylates histone H1, which suggested phosphorylation might regulate nonenzymatic proteins. The 1970s included the discovery of calmodulin-dependent protein kinases and the finding that proteins can be phosphorylated on more than one amino acid residue. The 1990s may be described as the "decade of protein kinase cascades".
All of astatine's isotopes are short-lived; the most stable is astatine-210, with a half-life of 8.1 hours. There are 41 known isotopes of astatine, with mass numbers of 188 and 190–229. Theoretical modeling suggests that about 37 more isotopes could exist. No stable or long-lived astatine isotope has been observed, nor is one expected to exist. Astatine's alpha decay energies follow the same trend as for other heavy elements. Lighter astatine isotopes have quite high energies of alpha decay, which become lower as the nuclei become heavier. Astatine-211 has a significantly higher energy than the previous isotope, because it has a nucleus with 126 neutrons, and 126 is a magic number corresponding to a filled neutron shell. Despite having a similar half-life to the previous isotope (8.1 hours for astatine-210 and 7.2 hours for astatine-211), the alpha decay probability is much higher for the latter: 41.81% against only 0.18%. The two following isotopes release even more energy, with astatine-213 releasing the most energy. For this reason, it is the shortest-lived astatine isotope. Even though heavier astatine isotopes release less energy, no long-lived astatine isotope exists, because of the increasing role of beta decay (electron emission). This decay mode is especially important for astatine; as early as 1950 it was postulated that all isotopes of the element undergo beta decay, though nuclear mass measurements indicate that 215At is in fact beta-stable, as it has the lowest mass of all isobars with A = 215.
== External links == The MEROPS online database for peptidases and their inhibitors: M13.001 Archived 2019-09-12 at the Wayback Machine Neprilysin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P08473 (Neprilysin) at the PDBe-KB. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.